메뉴 건너뛰기




Volumn 17, Issue 6, 2012, Pages 171-176

Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

EID: 84870882706     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2011-100388     Document Type: Review
Times cited : (36)

References (40)
  • 2
    • 8744240727 scopus 로고    scopus 로고
    • Determinants of quality of life in patients with psoriasis: A study from the US population
    • Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8.
    • (2004) J Am Acad Dermatol , vol.51 , pp. 704-708
    • Gelfand, J.M.1    Feldman, S.R.2    Stern, R.S.3
  • 3
    • 53349119980 scopus 로고    scopus 로고
    • The impact of psoriasis on health care costs and patient work loss
    • Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008;59:772-80.
    • (2008) J Am Acad Dermatol , vol.59 , pp. 772-780
    • Fowler, J.F.1    Duh, M.S.2    Rovba, L.3
  • 4
    • 79960593968 scopus 로고    scopus 로고
    • What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010
    • quiz 588-9
    • Foulkes AC, Grindlay DJ, Griffiths CE, et al. What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. Clin Exp Dermatol 2011;36:585-9; quiz 588-9.
    • (2011) Clin Exp Dermatol , vol.36 , pp. 585-589
    • Foulkes, A.C.1    Grindlay, D.J.2    Griffiths, C.E.3
  • 5
    • 23644442757 scopus 로고    scopus 로고
    • Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis
    • Malhotra S, Bansal D, Shafiq N, et al. Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis. Expert Opin Pharmacother 2005;6:1455-61.
    • (2005) Expert Opin Pharmacother , vol.6 , pp. 1455-1461
    • Malhotra, S.1    Bansal, D.2    Shafiq, N.3
  • 7
    • 0018099294 scopus 로고
    • Severe psoriasis - Oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
    • (1978) Dermatologica , vol.157 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 8
    • 34248335482 scopus 로고    scopus 로고
    • New method being developed for assessing psoriasis. NPF psoriasis score - Your input needed
    • Krueger G. New method being developed for assessing psoriasis. NPF psoriasis score - your input needed. National Psoriasis Foundation Psoriasis Forum 1999;5:1-5.
    • (1999) National Psoriasis Foundation Psoriasis Forum , vol.5 , pp. 1-5
    • Krueger, G.1
  • 9
    • 4644309388 scopus 로고    scopus 로고
    • Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment
    • Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-9.
    • (2004) J Am Acad Dermatol , vol.51 , pp. 563-569
    • Langley, R.G.1    Ellis, C.N.2
  • 10
    • 77749326687 scopus 로고    scopus 로고
    • Evidence-based recommendations to assess psoriasis severity: Systematic literature review and expert opinion of a panel of dermatologists
    • Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2010;24 Suppl 2:2-9.
    • (2010) J Eur Acad Dermatol Venereol , vol.24 , Issue.SUPPL. 2 , pp. 2-9
    • Paul, C.1    Gourraud, P.A.2    Bronsard, V.3
  • 11
    • 19244365650 scopus 로고    scopus 로고
    • Thiazolidinediones
    • Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
    • (2004) N Engl J Med , vol.351 , pp. 1106-1118
    • Yki-Järvinen, H.1
  • 13
    • 0031003829 scopus 로고    scopus 로고
    • Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
    • Morikang E, Benson SC, Kurtz TW, et al. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10:440-6.
    • (1997) Am J Hypertens , vol.10 , pp. 440-446
    • Morikang, E.1    Benson, S.C.2    Kurtz, T.W.3
  • 14
    • 0031886864 scopus 로고    scopus 로고
    • The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
    • Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
    • (1998) Nature , vol.391 , pp. 79-82
    • Ricote, M.1    Li, A.C.2    Willson, T.M.3
  • 15
    • 0034030527 scopus 로고    scopus 로고
    • Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation
    • Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000;136:609-16.
    • (2000) Arch Dermatol , vol.136 , pp. 609-616
    • Ellis, C.N.1    Varani, J.2    Fisher, G.J.3
  • 16
    • 0032742408 scopus 로고    scopus 로고
    • Pharmacological peroxisome proliferator-activated receptorgamma ligands: Emerging clinical indications beyond diabetes
    • Pershadsingh HA. Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes. Expert Opin Investig Drugs 1999;8:1859-72.
    • (1999) Expert Opin Investig Drugs , vol.8 , pp. 1859-1872
    • Pershadsingh, H.A.1
  • 17
    • 13244286538 scopus 로고    scopus 로고
    • Pioglitazone: A promising therapy for psoriasis
    • Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 2005;152:189-91.
    • (2005) Br J Dermatol , vol.152 , pp. 189-191
    • Robertshaw, H.1    Friedmann, P.S.2
  • 18
    • 33750135442 scopus 로고    scopus 로고
    • Thiazolidinediones: Potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease
    • Varani J, Bhagavathula N, Ellis CN, et al. Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opin Investig Drugs 2006;15:1453-68.
    • (2006) Expert Opin Investig Drugs , vol.15 , pp. 1453-1468
    • Varani, J.1    Bhagavathula, N.2    Ellis, C.N.3
  • 19
    • 39149102510 scopus 로고    scopus 로고
    • Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study
    • Brauchli YB, Jick SS, Curtin F, et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol 2008;58:421-9.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 421-429
    • Brauchli, Y.B.1    Jick, S.S.2    Curtin, F.3
  • 20
    • 12344282955 scopus 로고    scopus 로고
    • Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study
    • Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005;44:126-9.
    • (2005) Rheumatology (Oxford) , vol.44 , pp. 126-129
    • Bongartz, T.1    Coras, B.2    Vogt, T.3
  • 21
    • 0031763298 scopus 로고    scopus 로고
    • Treatment of psoriasis with troglitazone therapy
    • Pershadsingh HA, Sproul JA, Benjamin E, et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998;134:1304-5.
    • (1998) Arch Dermatol , vol.134 , pp. 1304-1305
    • Pershadsingh, H.A.1    Sproul, J.A.2    Benjamin, E.3
  • 22
    • 17444404606 scopus 로고    scopus 로고
    • Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6)
    • Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005;44:328-33.
    • (2005) Int J Dermatol , vol.44 , pp. 328-333
    • Shafiq, N.1    Malhotra, S.2    Pandhi, P.3
  • 23
    • 65349091931 scopus 로고    scopus 로고
    • Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial
    • Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009;145:387-93.
    • (2009) Arch Dermatol , vol.145 , pp. 387-393
    • Mittal, R.1    Malhotra, S.2    Pandhi, P.3
  • 25
    • 34250633274 scopus 로고    scopus 로고
    • Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone
    • Ellis CN, Barker JN, Haig AE, et al. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 2007;8:93-102.
    • (2007) Am J Clin Dermatol , vol.8 , pp. 93-102
    • Ellis, C.N.1    Barker, J.N.2    Haig, A.E.3
  • 27
    • 33748935095 scopus 로고    scopus 로고
    • The case of the misleading funnel plot
    • Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ 2006;333:597-600.
    • (2006) BMJ , vol.333 , pp. 597-600
    • Lau, J.1    Ioannidis, J.P.2    Terrin, N.3
  • 28
    • 2542445474 scopus 로고    scopus 로고
    • A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    • Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
    • (2004) J Am Acad Dermatol , vol.50 , pp. 859-866
    • Carlin, C.S.1    Feldman, S.R.2    Krueger, J.G.3
  • 29
    • 0042625001 scopus 로고    scopus 로고
    • Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
    • Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
    • (2003) N Engl J Med , vol.349 , pp. 658-665
    • Heydendael, V.M.1    Spuls, P.I.2    Opmeer, B.C.3
  • 30
    • 0022461338 scopus 로고
    • Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes
    • Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
    • (1986) Dermatologica , vol.172 , pp. 298-304
    • Lindegård, B.1
  • 33
    • 33751181855 scopus 로고    scopus 로고
    • Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
    • Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
    • (2006) Arch Dermatol Res , vol.298 , pp. 321-328
    • Sommer, D.M.1    Jenisch, S.2    Suchan, M.3
  • 34
    • 33749662118 scopus 로고    scopus 로고
    • Prevalence of cardiovascular risk factors in patients with psoriasis
    • Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
    • (2006) J Am Acad Dermatol , vol.55 , pp. 829-835
    • Neimann, A.L.1    Shin, D.B.2    Wang, X.3
  • 36
    • 0034604248 scopus 로고    scopus 로고
    • Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
    • Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
    • (2000) Circulation , vol.102 , pp. 42-47
    • Festa, A.1    D'Agostino Jr., R.2    Howard, G.3
  • 37
    • 3042741188 scopus 로고    scopus 로고
    • The inflammatory response in mild and in severe psoriasis
    • Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917-28.
    • (2004) Br J Dermatol , vol.150 , pp. 917-928
    • Rocha-Pereira, P.1    Santos-Silva, A.2    Rebelo, I.3
  • 38
    • 1442275317 scopus 로고    scopus 로고
    • Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes
    • Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
    • (2004) Diabetes Care , vol.27 , pp. 813-823
    • Pickup, J.C.1
  • 39
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 40
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18.
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1    Ouellet-Hellstrom, R.2    Macurdy, T.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.